183 related articles for article (PubMed ID: 35559802)
1. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
Jenei K; Raymakers A; Meyers DE; Prasad V
J Cancer Policy; 2021 Dec; 30():100311. PubMed ID: 35559802
[TBL] [Abstract][Full Text] [Related]
2. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
Kim MS; Xu A; Haslam A; Prasad V
Int J Cancer; 2022 Jun; 150(11):1905-1910. PubMed ID: 35182072
[TBL] [Abstract][Full Text] [Related]
3. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of Sex- and Gender-Based Analyses in Oncology Clinical Trials.
Hall M; Krishnanandan VA; Cheung MC; Coburn NG; Haas B; Chan KKW; Raphael MJ
J Natl Cancer Inst; 2022 Aug; 114(8):1186-1191. PubMed ID: 35477781
[TBL] [Abstract][Full Text] [Related]
5. Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.
Dymanus KA; Butaney M; Magee DE; Hird AE; Luckenbaugh AN; Ma MW; Hall ME; Huelster HL; Laviana AA; Davis NB; Terris MK; Klaassen Z; Wallis CJD
Cancer; 2021 Sep; 127(17):3156-3162. PubMed ID: 34160824
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
[TBL] [Abstract][Full Text] [Related]
7. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
[TBL] [Abstract][Full Text] [Related]
8. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022.
Xie JS; Kaur H; Tao B; Lee J; Solish D; Kohly R; Margolin E
JAMA Ophthalmol; 2024 Feb; 142(2):123-130. PubMed ID: 38236588
[TBL] [Abstract][Full Text] [Related]
9. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
Elbaz J; Haslam A; Prasad V
Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
[TBL] [Abstract][Full Text] [Related]
10. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
11. US Food and Drug Administration regulatory updates in neuro-oncology.
Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
[TBL] [Abstract][Full Text] [Related]
12. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
Zettler ME
Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
[TBL] [Abstract][Full Text] [Related]
13. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
15. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020.
Olivier T; Haslam A; Prasad V
BMC Cancer; 2023 May; 23(1):448. PubMed ID: 37198564
[TBL] [Abstract][Full Text] [Related]
16. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021.
Wilson BE; Nadler MB; Desnoyers A; Booth CM; Amir E
Cancer; 2024 Jan; 130(2):276-286. PubMed ID: 37751315
[TBL] [Abstract][Full Text] [Related]
18. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
20. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
